“Tuberculosis (TB) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Tuberculosis Market.
The Tuberculosis Pipeline report embraces in-depth commercial, regulatory, and Tuberculosis clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Tuberculosis drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Tuberculosis (TB) Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the emerging therapies for Tuberculosis treatment and the aggregate therapies developed by major pharma companies.
-
It accesses the different Tuberculosis therapies segmented into early-stage, mid-stage, and late-stage clinical development.
-
It outlines the major Tuberculosis companies involved in targeted therapeutics development, with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the Tuberculosis drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Tuberculosis therapeutic market.
Tuberculosis (TB) Therapeutics Landscape
Treatment for TB usually involves taking antibiotics for several months. While TB is a serious condition that can be fatal if left untreated, deaths are rare if treatment is completed. Most people do not need to be admitted to the hospital during treatment. TB is a treatable and curable disease. Drug-susceptible TB disease is treated with a standard 4-month or 6-month course of 4 antimicrobial drugs that are provided with support to the patient by a health worker or trained treatment supporter. Without such support, treatment adherence is more difficult.
Several companies are working to develop treatment for Tuberculosis. AJVaccines has developed BCG Vaccine “AJ Vaccines” for the prevention of TB. Also, the company has developed Tuberculin PPD RT23 for the diagnosis of Tuberculosis. The name of the vaccine and the product may differ between countries.
There are approx. 35+ key companies developing therapies for Tuberculosis. Currently, Qurient Co. is leading the therapeutics market with its Tuberculosis drug candidates in the mid to advanced stage of clinical development.
Tuberculosis Companies Actively Working in the Therapeutic Market Include:
-
Serum Institute of India Pvt. Ltd.
-
AnHui Longcom Biologic Pharmacy
-
Biofabri, S.L
-
Immunitor LLC
-
Shanghai Jiatan Pharmatech
-
GlaxoSmithKline
-
Archivel Farma S.L.
-
LegoChem Biosciences
-
Quratis Inc
-
Aeras
-
Qurient Co.
-
Sequella, Inc.
-
Otsuka Pharmaceutical
-
Vaxil Biotherapeutics
-
Faron Pharmaceuticals
-
Tianjin CanSino Biotechnology
-
Global Alliance for TB Drug Development
-
Spero Therapeutics
And Many Others
Emerging and Marketed Tuberculosis Drugs Covered in the Report Include:
-
Telacebec (Q203): Qurient Co
-
VPM1002: Serum Institute of India
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Tuberculosis Companies Working in the Market @
https://www.delveinsight.com/sample-request/tuberculosis-pipeline-insight
Analysis of Emerging Tuberculosis Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued and inactive candidates
Route of Administration
Tuberculosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Oral
-
Parenteral
-
Intravenous
-
Subcutaneous
-
Topical
Molecule Type
Products have been categorized under various Molecule types such as
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
Learn How the Tuberculosis Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @
https://www.delveinsight.com/sample-request/tuberculosis-pipeline-insight
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Tuberculosis Treatment Patterns
4. Tuberculosis – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Tuberculosis Late Stage Products (Phase-III)
7. Tuberculosis Mid-Stage Products (Phase-II)
8. Tuberculosis Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Tuberculosis Discontinued Products
13. Tuberculosis Product Profiles
14. Major Tuberculosis Companies in the Market
15. Key Products in the Tuberculosis Therapeutics Segment
16. Dormant and Discontinued Products
17. Tuberculosis Unmet Needs
18. Tuberculosis Future Perspectives
19. Tuberculosis Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
https://www.delveinsight.com/sample-request/tuberculosis-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
“Tendonitis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Tendonitis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Tendonitis market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices